Heparin-coated stents

被引：0

作者：

Kocsis, JF

Llanos, G

Holmer, E

机构：

[1] Cordis, Warren, NJ 07059 USA

[2] Carmeda AB, SE-11347 Stockholm, Sweden

来源：

JOURNAL OF LONG-TERM EFFECTS OF MEDICAL IMPLANTS | 2000年 / 10卷 / 1-2期

关键词：

heparin; stents; subacute thrombosis; blood compatibility;

D O I：

10.1615/JLongTermEffMedImplants.v10.i12.50

中图分类号：

R318 [生物医学工程];

学科分类号：

0831 ;

摘要：

Stenting has revolutionized the field of interventional cardiology. However, early stud ies revealed a high incidence of thrombotic occlusion of the stent and significant bleeding complications resulting from the use of intensive anticoagulation after implantation. One of the strategies used to reduce stent thrombosis and hemorrhagic complications has been to decrease the thrombogenicity of the stent surface. For this purpose, a unique heparin surface patented by Carmeda AB (Stockholm, Sweden)-the Carmeda(R) BioActive Surface (CBAS)-has been coated onto Cordis(R) (Johnson & Johnson) stents. Preclinical evaluations of the thromboresistance of heparin-coated stents and clinical studies of heparin-coated stents in a variety of clinical settings are discussed.

引用

页码：19 / 45

页数：27

共 108 条

[11]

Blasini R, 1997, CATHETER CARDIO DIAG, V42, P113, DOI 10.1002/(SICI)1097-0304(199710)42:2<113::AID-CCD2>3.0.CO

[12]

2-G

[13] LOW-MOLECULAR-WEIGHT HEPARIN REDUCES NEOINTIMAL PROLIFERATION AFTER CORONARY STENT IMPLANTATION IN HYPERCHOLESTEROLEMIC MINIPIGS [J].